Últimas noticias sobre SI-BONE (NASDAQ:SIBN) Bolsa

SI-BONE

SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.

SI-BONE Inc

Analyst Drew Ranieri of Morgan Stanley maintained a Buy rating on SI-Bone (SIBN – Research Report), retaining the price target of $19.00. Drew Rani...

Buy Rating Justified: SI-Bone's Growth Potential and Market Expansion Opportunities

SI-BONE (SIBN) announced that the Centers for Medicare & Medicaid Services, CMS, has granted Transitional Pass-Through, TPT, payment status for the...

SI-Bone receives TPT status for iFuse Bedrock Granite

SI-BONE GAAP EPS of -$0.16 beats by $0.08, revenue of $40.3M misses by $0.19M

Reports Q3 revenue $40.34M, consensus $40.5M. "The team did a tremendous job delivering record worldwide revenue and getting close to Adjusted EBIT...

SI-Bone reports Q3 EPS (16c), consensus (24c)

Consensus $165.94M. The company said, "SI-BONE (SIBN) is updating 2024 worldwide revenue guidance to be in the range of $165 million to $166 millio...

SI-Bone narrows FY24 revenue view to $165M-$166M from $165M-$167M

SI-BONE, Inc. (SIBN) Q3 2024 Earnings Call Transcript

Si-Bone ( ($SIBN) ) has released its Q3 earnings. Here is a breakdown of the information Si-Bone presented to its investors. SI-BONE, Inc., a leadi...

SI-BONE Reports Strong Q3 Growth and Optimistic Outlook

JMP Securities analyst David Turkaly reiterated a Buy rating on SI-Bone (SIBN – Research Report) today and set a price target of $32.00. David Turk...

SI-Bone's Strong Sales Growth and Innovative Product Pipeline Support Continued Buy Rating

Analyst Drew Ranieri from Morgan Stanley maintained a Buy rating on SI-Bone (SIBN – Research Report) and keeping the price target at $19.00. Drew R...

SI-Bone's Resilience and Growth Potential Amid Challenges: Analyst Maintains Buy Rating

Truist raised the firm's price target on SI-Bone (SIBN) to $18 from $16 and keeps a Buy rating on the shares after its Q3 results. The quarter's po...

Comments

SI-BONE

Noticias

Últimas noticias sobre SI-BONE (NASDAQ:SIBN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL